Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAB08 in Systemic Lupus Erythematosus
NCT02711813Phase 2Terminated
- Sponsor
- TheraMAB
- Start
- Mar 2016
- Primary completion
- May 2018
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of theralizumab in systemic lupus erythematosus (SLE) (3 arms), sponsored by TheraMAB. Primary endpoints: SLE Responder Index at 24 weeks and Adverse Events at 24 weeks. Started Mar 2016; status: terminated.
02
Drugs
theralizumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02711813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02711813.